SPOTLIGHT: Organogenesis plans fast-paced expansion


Organogenesis CEO Geoff MacKay tells the Boston Globe about the reasons why the developer is staying and expanding at new facilities in Massachusetts. And he also discusses his "tight timeline" to expand production and gain new approvals over the next three to four years. Report

Suggested Articles

What a difference a day makes in biotech.

A report out this week by PwC thinks that biotech could be in for a good year for deals as it sees the momentum from 2019 growing.

A drug developed at Temple restores a mechanism in brain cells that prevents the toxic buildup of the proteins amyloid beta and tau in Alzheimer's.